文 献5）Kim H, George E, Ragland R, Rafail S, Zhang R, Krepler C, et al. Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models. Clin Cancer Res 2017; 23: 3097-108.6）Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, et al. Progesterone receptor modulates ERα action in breast cancer. Nature 2015; 523: 313-7.7）Centenera MM, Hickey TE, Jindal S, Ryan NK, Ravindranathan P, Mohammed H, et al. A patient-derived explant (PDE) model of hormone-dependent cancer. Mol Oncol 2018; 12: 1608-22.1161）DWHO Classification of tumours Female Genital Tumours, 5th Edition. Lyon, France: International Agency of Research on Cancer, 2020.2）Pors J, Segura S, Chiu DS, Almadani N, Ren H, Fix DJ, et al. Clinicopathologic characteristics of mesonephric adenocarcinomas and mesonephric-like adenocarcinomas in the gynecologic tract: a multi-institutional study. Am J Surg Pathol 2021; 45: 498-506.3）Tuveson D, Clevers H. Cancer modeling meets human organoid technology. Science 2019; 364: 952-5.4）George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, et al. A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. JCI Insight 2017; 2: e89760.
元のページ ../index.html#130